Evidence map›Paper›PMID 39309488›Full record

ArticleActa pharmaceutica Sinica. B2024

An iron-based metal-organic framework nanoplatform for enhanced ferroptosis and oridonin delivery as a comprehensive antitumor strategy.

Mengru Cai, Tingting Fu, Rongyue Zhu, Panxiang Hu, Jiahui Kong, Shilang Liao, Yuji Du, Yongqiang Zhang, Changhai Qu, Xiaoxv Dong and 2 more

Abstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. CaMaterials today. Bio · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Potential role of SIRT1 in cell ferroptosis.Frontiers in cell and developmental biology · 2025
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mengru CaiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Tingting FuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Rongyue ZhuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Panxiang HuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Jiahui KongSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Shilang LiaoSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Yuji DuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Yongqiang ZhangSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Changhai QuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Xiaoxv DongSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Xingbin YinSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.
Jian NiSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ferroptosis is a recently discovered pathway for regulated cell death pathway. However, its efficacy is affected by limited iron content and intracellular ion homeostasis. Here, we designed a metal-organic framework (MOF)-based nanoplatform that incorporates calcium peroxide (CaO

Indexed as

Chemodynamic therapyFused cell membrane coatingImmunotherapyMetabolizationMetal-organic frameworksOridoninPhotodynamic therapySelf-amplifying ferroptosis

Identifiers

PMID39309488
PMCPMC11413704

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.